Yara Abdou
@YAbdouMD
Followers
523
Following
462
Media
22
Statuses
112
Breast Medical Oncologist | Clinical Trialist and Researcher @UNC_Lineberger | Former @JCO_ASCO Editorial Fellow. Views are my own. 🇺🇸🇸🇾
Chapel Hill, NC
Joined May 2024
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
PAVILLON DES FOLIES X SAROCHA
• 576001 Tweets
#PavillonDesFoliesxFREEN
• 570811 Tweets
BEAUTIFUL FRAGRANCE WITH BUILD
• 82026 Tweets
自民党石破総裁
• 68762 Tweets
#せっかくグルメ
• 53271 Tweets
イッテQ
• 43691 Tweets
John Kerry
• 39307 Tweets
ジャック
• 30642 Tweets
インライ
• 27507 Tweets
#amici24
• 23594 Tweets
モンスト
• 23039 Tweets
村上誠一郎
• 22426 Tweets
BBS RAIN
• 21269 Tweets
手越復帰
• 16689 Tweets
ツイステ
• 16240 Tweets
スカリー
• 14817 Tweets
ジャミル
• 14656 Tweets
Happy Birthday Daniel
• 12678 Tweets
勝平さん
• 12377 Tweets
Pinned Tweet
0
0
6
I didn’t think I would be a ribbon kinda gal, but got to admit I’m loving my rainbow
@asco
badge!!!
#ASCO24
@ConquerCancerFd
@JCO_ASCO
@ASCOTECAG
5
9
141
Excited and honored to present our newest race and ethnicity analysis from RxPONDER looking at recurrence score gene axes scores.
Join us May 31st at the Rapid Oral session, details 👇🏼
#bcsm
#ASCO24
@KalinskyKevin
1
7
43
Adding Pembro to SG did not improve PFS in unselected patients with HR+ MBC
Reporting negative findings is as important as reporting positive findings‼️
#ASCO24
@OncBrothers
@OncoAlert
#bcsm
1
10
34
Looks like switching your CDK4/6i is key for efficacy for post progression on CDK4/6i ‼️
@oreganruth
#bcsm
@OncoAlert
#ASCO24
1
13
31
Racial Disparities is a complex issue that requires a broader perspective in order to address it effectively.
Thank you
@hoperugo
for highlighting this remark 👇🏼
#ASCO24
@OncoAlert
#Disparities
#bcsm
1
8
30
Excited to join
@PamelaKunzMD
@GlopesMd
for the Publication 101: Peer Review & Becoming a Successful Author" panel discussion at the
@ASCOTECAG
lounge, moderated by
@NazliDizman
Join us on Monday, June 1st, between 12:00 pm and 12:45 pm.
@ASCO
#ASCO24
0
7
27
Spectacular work by
@KalinskyKevin
showing that low serum AMH could identify which patients can safely forgo adjuvant chemo
👉🏼Awaiting validation
#ASCO24
#bcsm
@OncoAlert
1
10
24
It is with a heavy heart that I share the news of the passing of an incredible human being- Dr. Shekinah Elmore. I am deeply fortunate to have known her. Her kindness, dedication, and unwavering spirit left a lasting impact on everyone she met. This is a profound loss for the
Words cannot describe how profoundly sad I am to share the news of Dr. Shekinah Elmore's death this week.
Shekinah was a SPECTACULAR human with profound wisdom, an incredible generosity of spirit, & a heart of kindness that lifted us all up.
34
83
253
1
4
21
Taking a moment to acknowledge that many places, especially in third world countries, lack access to essential drugs and resources. We are fortunate to have more in the US.
A shout out to Dr. O’Sullivan for acknowledging that treatment paradigms are not applicable everywhere, we
1
4
19
Excited to join
@PamelaKunzMD
@GlopesMd
for the Publication 101: Peer Review & Becoming a Successful Author" panel discussion at the
@ASCOTECAG
lounge, moderated by
@NazliDizman
Join us on Monday, June 1st, between 12:00 pm and 12:45 pm.
@ASCO
#ASCO24
0
7
27
0
3
15
What a spectacular session! Thanks
@ASCOTECAG
for having us!
PS: Next time we take a group picture, I'll try not to strike a dance pose 🤦🏽♀️
Peer Review and Becoming a Successful Author -- a wonderful presentation and discussion that is sure to become a staple in the
#TECLounge
. Thank you to our presenters
@YAbdouMD
,
@PamelaKunzMD
, Dr. Robert Maki, and
@NazliDizman
.
0
3
15
2
0
11
📣 First-in-human study of CAR- Monocytes in patients with HER2 positive solid tumors
Come check out our TIP poster 👇🏼
@CarismaTher
#bcsm
#ASCO24
@OncoAlert
1
5
11
Looking forward to this exciting discussion with Dr.
@prarthnavb
#bcsm
@TumorBoardTues
@yekeduz_emre
@DrYukselUrun
@PCFnews
@ProstateUK
@PCR_News
@HamidEmamekhoo
@JoshLangMD
@PGrivasMDPhD
@CParkMD
@DrChoueiri
@DrRanaMcKay
@NazliDizman
@AarmstrongDuke
@APCCC_Lugano
@neerajaiims
@montypal
@Prof_Nick_James
@jberchuck
@MikeSerzanMD
@Martin_AngelMD
🗓️TOMORROW, Tuesday June 25 at 8 PM ET,
@YAbdouMD
&
@prarthnavb
bring
#TumorBoardTuesday
updates in the treatment of HR+, HER2-
#mBC
!
1
3
6
0
0
11
0
4
10
A-Brave trial: adjuvant avelumab vs placebo in high risk TNBC
No significant improvement in DFS although statistical improvement in DDFS and OS were seen.
In high risk patients, I still offer adjuvant ICI if patients have not received neoadjuvantly, this data doesn’t suggest
0
4
8
@DrLisaCarey
eloquently discussing three presentations from today’s oral session
@ASCO
#bcsm
#ASCO24
@OncoAlert
@UNC_Lineberger
0
2
8
Important work presented by
@TarahBallinger
looking at treatment-induced peripheral neuropathy (TIPN)
in Black patients.
Every 3 weeks docetaxel was associated with less grade 2/3 and less dose reductions due to TIPN
This highlights the importance of studying treatments in a
0
1
7
postMONARCH: First phase 3 trial to show benefit of continued CDK4/6i with abemaciclib + fulvestrant post progression on CDK4/6i
All patients benefited although efficacy more pronounced in:
➡️>12 months prior cdk4/6i duration
➡️no visceral mets
Spectacular presentation by
0
1
7
@KNJobanputra
presenting great work on outcomes in intermediate and poor risk Nonseminomatous germ cell tumors in India.
#GlobalHealth
#ASCO24
#ASCOVMP
0
0
6
Thank you for the shout out
@Dr_AmerZeidan
!!!
The hacker
@PgambarRaj
took over my account and remains active despite being reported by many verified X users.
@X
does not seem to take impersonation seriously
#disappointed
A hacker took over
@YAbdouMD
original account including her followers & for reasons unclear to me that
@X
didn’t do anything about it. In any case Dr Abdou started a new account
@YAbdouMD
& she is the best so plz consider following her account
@acweyand
@AaronGoodman33
1
4
9
0
2
5
@GlopesMd
@VoglNY
@ASCO
@OncoAlert
@n8pennell
@NarjustFlorezMD
@Latinamd
@DrSGraff
@cancermd
@mtmdphd
Ha! I love this. They should hand this out in conference rooms.
0
1
3
DB06: phase3 of T-DXd vs TPC in chemo naive HR+/HER2 low and HER2-ultralow
➡️ improved PFS 🔼5.1m (13.2 vs 8.1, HR 0.62)
➡️consistent PFS improvement in ultralow subgroup 🔼4.9m
➡️OS still immature
➡️ILD in 11% of patients and remains an important safety risk
👏🏼 ~85% of HR+
0
0
6
@prarthnavb
@TumorBoardTues
@MPishvaian
@JohnEbbenMDPhD
@BCJoyceO
@ErikaHamilton9
@DrHBurstein
Also data from TBCRC 048 suggest activity in patients with germline PALB2 or somatic mutations in BRCA1 or BRCA2.
1
3
5
Looks like carboplatin improves EFS in early TNBC, but can we de-escalate the anthracycline? Awaiting the phase3 SCARLET study..
1
0
3
@prarthnavb
@TumorBoardTues
@MPishvaian
@JohnEbbenMDPhD
@BCJoyceO
@ErikaHamilton9
@DrHBurstein
Can also use talazoparib (EMBRACA)
1
2
4
@MPishvaian
@prarthnavb
@TumorBoardTues
@JohnEbbenMDPhD
@BCJoyceO
@ErikaHamilton9
@DrHBurstein
Breast is the best :)
0
2
3
Largest study evaluating ctDNA in early, high risk HR+ BC showing patients who remained persistently positive or became positive on treatment with abema were more likely to experience an IDFS event compared to patients with persistently negative ctDNA or if ctDNA became
0
0
3
@fumikochino
@ASCO
@ErinCobain
@IbiayiMD
@OncElias
@shilpaonc
@BHenickMD
@RyanNipp
@minasedrakmd
@GitaThanaMD
@NVijayvergiaMD
@MKnoll_MD
Congratulations 👏🏼🎊🍾 I hear its awesome!!!
0
0
3
0
2
3
@MPishvaian
@prarthnavb
@TumorBoardTues
@JohnEbbenMDPhD
@BCJoyceO
@ErikaHamilton9
YES! There is data, previously MAINTAIN and recently postMONARCH by
@KalinskyKevin
showing benefit from a cdk 4/6i post progression on cdk4/6i.
0
2
3
1
0
3
@MPishvaian
@prarthnavb
@TumorBoardTues
yes but we know from the right choice trial that even in symptomatic visceral crisis, first-line ribociclib plus ET showed a significant PFS benefit and similar response rates, over combination CT in these patients
1
2
3
1
0
2
INAVO120: Inavolisib with palbo and fulvestrant in PIK3CA-Mutant HR+ MBC
✅improved PFS (15m vs 7.3m, HR 0.43 )
✅ Delayed need for subsequent therapy (🔼8.9m)
✅Longer median time to deterioration in pain severity (🔼12.8m)
➡️ More drug = more toxicities although maintained
0
0
2
@tmprowell
@PTarantinoMD
@KalinskyKevin
Thank you Tatiana! Hope I get to see you !!! It’s been too long
0
0
2
@MPishvaian
@prarthnavb
@TumorBoardTues
@JohnEbbenMDPhD
@BCJoyceO
@ErikaHamilton9
Yes that's reasonable. We also have data suggesting that there is benefit in continuing a CDK4/6i following progression on a CDK4/6i :
postMONARCH
#ASCO24
@KalinskyKevin
0
1
2
@StoverLab
@OhioStateMedOnc
@OSUCCC_James
@OSUWexMed
@DrGattiMays
@quirogad
@Nicole_O_W
@sardesai_sagar
@nerealiamd
@royaryam
The best colleagues 😊
0
0
2
@MPishvaian
@prarthnavb
@TumorBoardTues
@JohnEbbenMDPhD
@BCJoyceO
@ErikaHamilton9
depends on the patient, some appreciate the week off, others prefer daily dosing
0
2
2
@CharuAggarwalMD
@HemOncToday
@PennCancer
@PennMedicine
@PennMDForum
@ShikhaJainMD
@marklewismd
@WimedicineOrg
@GoHealio
Congratulations!
0
0
2
@ramsedhom
@ASCO
@ASCOPres
@fischmd
@MDRoeland
@lynn_schuchter
@tomleblancMD
@AngieDemichele
@NarjustFlorezMD
@GlopesMd
@marklewismd
@oncology_bg
@csoncol
Amazing! Congratulations Ramy 👏🏼
0
0
1
@BrunaPellini
@MoffittNews
@MoffittResearch
@PatrickHwuMD
@lungoncdoc
@COlazagasti
@jorgesafe
@LygiaPellini
👏🏼 you are a rock star!!!
0
0
1
@NarjustFlorezMD
@royaryam
@ASCO
@Florez_Lab
@LatinasInMed
@DanaFarber
@DanaFarberNews
@DanaFarber_CGCM
@DFarberThoracic
Congratulations!!!
0
0
1
@prarthnavb
@TumorBoardTues
@MPishvaian
@JohnEbbenMDPhD
@BCJoyceO
There are no current randomized data comparing these 3 cdk4/6i, although an ongoing trial, HARMONIA (NCT05207709), will randomize first-line patients with metastatic HR + HER2-enriched breast cancer to receive endocrine therapy with either palbociclib or ribociclib. This trial
0
1
1